ICR Westwicke is an IPO advisory, capital markets advisory, and strategic communications firm. We provide integrated investor relations, public relations, and independent capital markets advice to small and mid-cap healthcare companies.
We work with private and public healthcare companies to help position their story properly with all critical stakeholders and to develop value-added strategies to build brand awareness, corporate reputation and enhance equity market value. Through an integrated approach, we provide a one-stop-shop for the full spectrum of communications needs across the entire corporate lifecycle from early stage start-up to mature public company.
Our background is unique. Our investor relations partners all come directly from Wall Street as former sell-side research analysts, institutional salesmen, investment bankers, equity capital markets professionals, buy-side analysts and portfolio managers, while our public relations team are former agency veterans, corporate communications executives and journalists.
Learn more
Latest Blog Posts
-
October 20th, 2021
4 Benefits of Conducting a Perception Audit
Do you know how the investment community views your company, including your products, leadership team, business strategy, and financial performance? Asking the tough questions and opening your company up to potential negative feedback can be a scary prospect, but it’s well worth it. By conducting a perception audit — an independent investigation into investor and analyst […]
-
October 10th, 2021
Get Quoted: 5 Tips for Engaging with the Media
Securing media coverage can be a critical opportunity for any company. Learn how to take advantage of interviews with bulletproof quotes.
-
September 23rd, 2021
Challenges and Opportunities In Early-Stage Biotech Funding
The biotech market has been growing rapidly over the past two decades, and is expected to be worth nearly $2.5 trillion by 2028. Meanwhile, the pace of technological developments and innovation have reduced barriers to entry, leading to an influx of aspiring biotech startups eager to bring their products to market. But despite the increase […]
